Pivotal readout
Oral ICOTYDE hits phase 3 goal in biologic-naive psoriatic arthritis
Johnson & Johnson said 58% of adults with active psoriatic arthritis who had never taken a biologic reached ACR20 at week 16 on ICOTYDE, versus 41% on placebo. ACR50 rates were 29% and 16%, and skin measures also favored the oral peptide. No new safety signals emerged through week 24; the drug is not yet approved for this use.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.